Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Finch Therapeutics Group, Inc.FNCH · Entity 90094 | Chief Business & Legal Officer | October 21, 2022 | October 25, 2022 |
| PepGen Inc.PEPG · Entity 6253 | Chief Business & Legal Officer | March 01, 2026 | March 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Finch Therapeutics Group, Inc.
Report date October 21, 2022 · Filed October 25, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,364 |
Reported balance
After 2022-10-21 transaction · row 1
1 source rowRow 1 · 2022-10-21 · Sale · Disposed 3,636 · Balance 31,364 F1: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2: Represents the weighted average price of shares sold by the broker on behalf of certain executive officers and employees of the company on October 21, 2022. The broker sold, in the aggregate on behalf of such employees, 21,137 shares in transactions ranging from $1.31 to $1.44 with a weighted average price of $1.39. The proceeds of all such sales were allocated to applicable employees on a pro rata basis based on the number of shares sold by such person. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2: Represents the weighted average price of shares sold by the broker on behalf of certain executive officers and employees of the company on October 21, 2022. The broker sold, in the aggregate on behalf of such employees, 21,137 shares in transactions ranging from $1.31 to $1.44 with a weighted average price of $1.39. The proceeds of all such sales were allocated to applicable employees on a pro rata basis based on the number of shares sold by such person. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
PepGen Inc.
Report date March 01, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,717 |
Reported balance
After 2026-03-01 transaction · row 1
1 source rowRow 1 · 2026-03-01 · Grant · Acquired 30,717 · Balance 65,717 F1: Consists of 30,717 restricted stock units ("RSUs"), each representing the contingent right to receive one share of Common Stock upon vesting. The RSUs vest in equal annual installments over four years, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.22 · Expires 2036-02-29 | Direct | 120,000 |
Reported balance
After 2026-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-01 · Grant · Acquired 120,000 · Balance 120,000 F2: This option shall vest and become exercisable as follows: 25% of the shares on the one-year anniversary of the Grant Date, with the remaining 75% vesting and becoming exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of 30,717 restricted stock units ("RSUs"), each representing the contingent right to receive one share of Common Stock upon vesting. The RSUs vest in equal annual installments over four years, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F2: This option shall vest and become exercisable as follows: 25% of the shares on the one-year anniversary of the Grant Date, with the remaining 75% vesting and becoming exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMAG PHARMACEUTICALS, INC.
Report date November 16, 2020 · Filed November 17, 2020
Section 16 reporting ended · disclosed 2020-11-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 1
1 source rowRow 1 · 2020-11-16 · Disposition to issuer · Disposed 92,244 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. F3: A portion of this amount consists of unvested performance-based restricted stock units ("PRSUs") at the target amount that could have been delivered pursuant to the award. Each Company PRSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such PRSU that would vest at the higher of (i) 100% target performance level, multiplied by a fraction, the numerator of which shall be the number of calendar days from the first day of the Company PRSU's performance measurement period to the Expiration Date and the denominator of which shall be the number of days in the Company PRSU's performance measurement period, or F4: (ii) the actual level of achievement of performance goals, calculated from the first day of the Company PRSU's performance measurement period through the end of the calendar month immediately preceding the Expiration Date, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-16 · Disposition to issuer · Disposed 30,000 · Balance 0 F5: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-16 · Disposition to issuer · Disposed 20,000 · Balance 0 F5: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-16 · Disposition to issuer · Disposed 20,000 · Balance 0 F5: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-16 · Disposition to issuer · Disposed 20,000 · Balance 0 F5: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-16 · Disposition to issuer · Disposed 35,000 · Balance 0 F5: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.
F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.
F3: A portion of this amount consists of unvested performance-based restricted stock units ("PRSUs") at the target amount that could have been delivered pursuant to the award. Each Company PRSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such PRSU that would vest at the higher of (i) 100% target performance level, multiplied by a fraction, the numerator of which shall be the number of calendar days from the first day of the Company PRSU's performance measurement period to the Expiration Date and the denominator of which shall be the number of days in the Company PRSU's performance measurement period, or
F4: (ii) the actual level of achievement of performance goals, calculated from the first day of the Company PRSU's performance measurement period through the end of the calendar month immediately preceding the Expiration Date, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.
F5: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
bluebird bio, Inc.
Report date May 30, 2025 · Filed June 03, 2025
Section 16 reporting ended · disclosed 2025-06-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-06-02 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-05-30 · Other · Disposed 1,143 · Balance 3,125 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Row 2 · 2025-06-02 · Disposition to issuer · Disposed 3,125 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F4: (Continued from footnote 3) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time. Row 3 · 2025-06-02 · Grant · Acquired 2,500 · Balance 2,500 F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each performance-based restricted stock unit award with respect to shares that is, at the time of determination, subject to performance-based vesting or forfeiture conditions ("PSU Award") that is outstanding and vested as of immediately prior thereto, or which shall become vested as required under the terms governing the PSU Award, shall by virtue of the Merger automatically and (except as otherwise provided in the Merger Agreement) without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F6: (Continued from footnote 5) (i) an amount in cash equal to the product of the number of shares underlying such PSU Award immediately prior to the Effective Time (assuming that the applicable performance goals have been deemed to be achieved at the greater of target and actual level of performance as determined by the Compensation Committee of the Issuer's board of directors in its discretion) and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each such share subject to such PSU Award immediately prior to the Effective Time. Row 4 · 2025-06-02 · Disposition to issuer · Disposed 2,500 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each performance-based restricted stock unit award with respect to shares that is, at the time of determination, subject to performance-based vesting or forfeiture conditions ("PSU Award") that is outstanding and vested as of immediately prior thereto, or which shall become vested as required under the terms governing the PSU Award, shall by virtue of the Merger automatically and (except as otherwise provided in the Merger Agreement) without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F6: (Continued from footnote 5) (i) an amount in cash equal to the product of the number of shares underlying such PSU Award immediately prior to the Effective Time (assuming that the applicable performance goals have been deemed to be achieved at the greater of target and actual level of performance as determined by the Compensation Committee of the Issuer's board of directors in its discretion) and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each such share subject to such PSU Award immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price").
F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive
F4: (Continued from footnote 3) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time.
F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each performance-based restricted stock unit award with respect to shares that is, at the time of determination, subject to performance-based vesting or forfeiture conditions ("PSU Award") that is outstanding and vested as of immediately prior thereto, or which shall become vested as required under the terms governing the PSU Award, shall by virtue of the Merger automatically and (except as otherwise provided in the Merger Agreement) without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive
F6: (Continued from footnote 5) (i) an amount in cash equal to the product of the number of shares underlying such PSU Award immediately prior to the Effective Time (assuming that the applicable performance goals have been deemed to be achieved at the greater of target and actual level of performance as determined by the Compensation Committee of the Issuer's board of directors in its discretion) and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each such share subject to such PSU Award immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2026 Filed Mar 2, 2026 17:09 UTC | PepGen Inc. PEPG · Entity 6253 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001835597-26-000010 · form4.xml · derivative · entry 2 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2036-02-29 F2 · derivative.exercise_date: This option shall vest and become exercisable as follows: 25% of the shares on the one-year anniversary of the Grant Date, with the remaining 75% vesting and becoming exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| March 01, 2026 Filed Mar 2, 2026 17:09 UTC | PepGen Inc. PEPG · Entity 6253 | GrantCommon Stock | 30,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001835597-26-000010 · form4.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,717 F1 · shares: Consists of 30,717 restricted stock units ("RSUs"), each representing the contingent right to receive one share of Common Stock upon vesting. The RSUs vest in equal annual installments over four years, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 17:08 UTC | PepGen Inc. PEPG · Entity 6253 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001835597-25-000009 · form4.xml · derivative · entry 2 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2035-12-07 F2 · derivative.exercise_date: This option shall vest as follows: twenty-five percent (25%) on the one-year anniversary of the Grant Date and the remainder vesting in thirty-six (36) equal monthly installments, subject to the Reporting Person's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 17:08 UTC | PepGen Inc. PEPG · Entity 6253 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001835597-25-000009 · form4.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 F1 · date: Consists of shares of Common Stock issuable under 35,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on December 8, 2026, subject to the Reporting Person's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 18:02 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Disposition to issuerCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-081175 · ownership.xml · nonDerivative · entry 4 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F5 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each performance-based restricted stock unit award with respect to shares that is, at the time of determination, subject to performance-based vesting or forfeiture conditions ("PSU Award") that is outstanding and vested as of immediately prior thereto, or which shall become vested as required under the terms governing the PSU Award, shall by virtue of the Merger automatically and (except as otherwise provided in the Merger Agreement) without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F6 · price: (Continued from footnote 5) (i) an amount in cash equal to the product of the number of shares underlying such PSU Award immediately prior to the Effective Time (assuming that the applicable performance goals have been deemed to be achieved at the greater of target and actual level of performance as determined by the Compensation Committee of the Issuer's board of directors in its discretion) and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each such share subject to such PSU Award immediately prior to the Effective Time. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 18:02 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-081175 · ownership.xml · nonDerivative · entry 3 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 F5 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each performance-based restricted stock unit award with respect to shares that is, at the time of determination, subject to performance-based vesting or forfeiture conditions ("PSU Award") that is outstanding and vested as of immediately prior thereto, or which shall become vested as required under the terms governing the PSU Award, shall by virtue of the Merger automatically and (except as otherwise provided in the Merger Agreement) without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F6 · price: (Continued from footnote 5) (i) an amount in cash equal to the product of the number of shares underlying such PSU Award immediately prior to the Effective Time (assuming that the applicable performance goals have been deemed to be achieved at the greater of target and actual level of performance as determined by the Compensation Committee of the Issuer's board of directors in its discretion) and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each such share subject to such PSU Award immediately prior to the Effective Time. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 18:02 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Disposition to issuerCommon Stock | 3,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-081175 · ownership.xml · nonDerivative · entry 2 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F4 · price: (Continued from footnote 3) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 18:02 UTC | bluebird bio, Inc. BLUE · Entity 78923 | OtherCommon Stock | 1,143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-081175 · ownership.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,125 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2 · price: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 16:14 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 238 | $7.39 | $1,759.42 |
DisclosureSEC source: 0001562180-25-000951 · primarydocument.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,501 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $7.27 to $7.55. The average weighted price was $7.3925. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: The number of securities reported herein have been adjusted to reflect a 1-for-20 reverse stock split effected by the Issuer on December 12, 2024. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 16:06 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-007130 · primarydocument.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,783 F1 · security: These restricted stock units for common stock vest over a four-year period at the rate of 25% on each of March 1, 2025, March 1, 2026, March 1, 2027 and March 1, 2028. These restricted stock units were approved during the Issuer's regular annual review cycle for 2024 with a delayed date of issuance. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 17:40 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 199,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001562180-24-002308 · primarydocument.xml · derivative · entry 1 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,000 Underlying: Common Stock · 199,000 shares Expires 2034-03-01 F1 · derivative.exercise_date: This stock option will vest over a four-year period at the rate of 25% on the first anniversary of March 1, 2024, and then in equal monthly installments for the remaining 36 months. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 16:07 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 5,217 | $0.90 | $4,708.34 |
DisclosureSEC source: 0001562180-24-001096 · primarydocument.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,783 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $0.9011 to $0.9040. The average weighted price was $0.9025. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 16:05 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Options (Right to buy) · Derivative | 100,000 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-23-000901 · primarydocument.xml · derivative · entry 2 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-02-01 F2 · derivative.exercise_date: The stock option vests over a four-year period at the rate of 25% on 2/1/2024 and then in 36 equal monthly installments thereafter. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 16:05 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-000901 · primarydocument.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Restricted stock unit awards vest over a four-year period at the rate of 25% on 2/1/2024, 25% on 2/1/2025, 25% on 2/1/2026, and 25% on 2/1/2027. Read SEC document |
| October 21, 2022 Filed Oct 25, 2022 16:25 UTC | Finch Therapeutics Group, Inc. FNCH · Entity 90094 | SaleCommon Stock | 3,636 | $1.39 | $5,054.04 |
DisclosureSEC source: 0000899243-22-034122 · doc4.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,364 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: Represents the weighted average price of shares sold by the broker on behalf of certain executive officers and employees of the company on October 21, 2022. The broker sold, in the aggregate on behalf of such employees, 21,137 shares in transactions ranging from $1.31 to $1.44 with a weighted average price of $1.39. The proceeds of all such sales were allocated to applicable employees on a pro rata basis based on the number of shares sold by such person. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 17:05 UTC | Finch Therapeutics Group, Inc. FNCH · Entity 90094 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-022621 · doc4.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · shares: Represents restricted stock units ("RSUs"). One third (1/3) of the total number of RSUs granted vest on October 20, 2022, February 20, 2023 and June 20, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| February 25, 2022 Filed Feb 28, 2022 18:48 UTC | Finch Therapeutics Group, Inc. FNCH · Entity 90094 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $8.61 | $0.00 |
DisclosureSEC source: 0001209191-22-013767 · doc4.xml · derivative · entry 1 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-02-24 F1 · derivative.exercise_date: This option vests in equal monthly installments over a four-year period commencing on February 1, 2022, subject to the Reporting Person's continuous service as of the applicable vesting date. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 16:38 UTC | Finch Therapeutics Group, Inc. FNCH · Entity 90094 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $9.68 | $0.00 |
DisclosureSEC source: 0001209191-21-070782 · doc4.xml · derivative · entry 1 Vittiglio Joseph · CIK 0001551776 · Chief Business & Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-12-19 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on December 20, 2022, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| March 18, 2021 Filed Mar 18, 2021 21:33 UTC | Finch Therapeutics Group, Inc. FNCH · Entity 90094 | GrantEmployee Stock Option (right to buy) · Derivative | 60,578 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-021964 · doc4.xml · derivative · entry 2 Vittiglio Joseph · CIK 0001551776 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,578 Underlying: Common Stock · 60,578 shares Expires 2031-03-17 F2 · derivative.exercise_date: Twenty-percent (20%) of the shares subject to the option vest on December 7, 2021, and the remaining shares subject to the option shall vest in forty-eight (48) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| March 18, 2021 Filed Mar 18, 2021 21:33 UTC | Finch Therapeutics Group, Inc. FNCH · Entity 90094 | GrantEmployee Stock Option (right to buy) · Derivative | 34,616 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-021964 · doc4.xml · derivative · entry 1 Vittiglio Joseph · CIK 0001551776 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,616 Underlying: Common Stock · 34,616 shares Expires 2031-03-17 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 18, 2022, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:44 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 35,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126324 · a4.xml · derivative · entry 7 Vittiglio Joseph · CIK 0001551776 · Chief Business Officer, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires not disclosed F5 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F5 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F5 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F5 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:44 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126324 · a4.xml · derivative · entry 6 Vittiglio Joseph · CIK 0001551776 · Chief Business Officer, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F5 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F5 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F5 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F5 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:44 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126324 · a4.xml · derivative · entry 5 Vittiglio Joseph · CIK 0001551776 · Chief Business Officer, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F5 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F5 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F5 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F5 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:44 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126324 · a4.xml · derivative · entry 4 Vittiglio Joseph · CIK 0001551776 · Chief Business Officer, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F5 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F5 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F5 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F5 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:44 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126324 · a4.xml · derivative · entry 3 Vittiglio Joseph · CIK 0001551776 · Chief Business Officer, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F5 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F5 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F5 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F5 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:44 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126324 · a4.xml · derivative · entry 2 Vittiglio Joseph · CIK 0001551776 · Chief Business Officer, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F5 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F5 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F5 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F5 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:44 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerCommon Stock | 92,244 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126324 · a4.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · Chief Business Officer, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2 · shares: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. F3 · shares: A portion of this amount consists of unvested performance-based restricted stock units ("PRSUs") at the target amount that could have been delivered pursuant to the award. Each Company PRSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such PRSU that would vest at the higher of (i) 100% target performance level, multiplied by a fraction, the numerator of which shall be the number of calendar days from the first day of the Company PRSU's performance measurement period to the Expiration Date and the denominator of which shall be the number of days in the Company PRSU's performance measurement period, or F4 · shares: (ii) the actual level of achievement of performance goals, calculated from the first day of the Company PRSU's performance measurement period through the end of the calendar month immediately preceding the Expiration Date, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2 · price: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. F3 · price: A portion of this amount consists of unvested performance-based restricted stock units ("PRSUs") at the target amount that could have been delivered pursuant to the award. Each Company PRSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such PRSU that would vest at the higher of (i) 100% target performance level, multiplied by a fraction, the numerator of which shall be the number of calendar days from the first day of the Company PRSU's performance measurement period to the Expiration Date and the denominator of which shall be the number of days in the Company PRSU's performance measurement period, or F4 · price: (ii) the actual level of achievement of performance goals, calculated from the first day of the Company PRSU's performance measurement period through the end of the calendar month immediately preceding the Expiration Date, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 16:11 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 35,000 | Not disclosed Strike: $7.27 | Not disclosed |
DisclosureSEC source: 0001104659-20-032483 · a4.xml · derivative · entry 2 Vittiglio Joseph · CIK 0001551776 · CBO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-03-10 F3 · price: Not applicable. F4 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 16:11 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-032483 · a4.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · CBO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,244 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F2 · shares: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's 2019 Equity Incentive Plan(the "Plan") that will vest in three equal annual installments with the first installment vesting on March 10, 2021. F3 · price: Not applicable. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 17:49 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 1,138 | $7.75 | $8,819.50 |
DisclosureSEC source: 0001104659-20-029291 · a4.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · CBO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,244 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 4,000 restricted stock units ("RSUs") on March 2, 2020. F2 · balance_after: Reporting person's total beneficial ownership has been adjusted to reflect that no shares were awarded pursuant to the performance-based RSU award granted on February 23, 2017. The reporting person had previously reported beneficial ownership of 7,500 shares pursuant to the RSU award, which represented the target number of shares that could have been delivered based on the achievement of certain relative total stockholder return targets over a three year performance period, which were not met, and which target share amount was previously reported on a Form 4 filed on February 27, 2017. Read SEC document |
| February 25, 2020 Filed Feb 25, 2020 16:43 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 2,206 | $8.84 | $19,501.04 |
DisclosureSEC source: 0000792977-20-000016 · wf-form4_158266697117170.xml · nonDerivative · entry 2 Vittiglio Joseph · CIK 0001551776 · CBO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,882 F2 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 6,666 restricted stock units on February 25, 2020. Read SEC document |
| February 23, 2020 Filed Feb 25, 2020 16:43 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 867 | $9.50 | $8,236.50 |
DisclosureSEC source: 0000792977-20-000016 · wf-form4_158266697117170.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · CBO, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,088 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 2,501 restricted stock units on February 23, 2020. Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 16:41 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | SaleCommon Stock | 1,425 | $14.01 | $19,964.25 |
DisclosureSEC source: 0000792977-19-000052 · wf-form4_155233688756441.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,955 F1 · shares: The reported transaction on this Form 4 was automatically effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2018 in order to cover incremental taxes on the vesting of previous restricted stock unit grants. Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 18:07 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 1,146 | $14.76 | $16,914.96 |
DisclosureSEC source: 0000792977-19-000046 · wf-form4_155182724598001.xml · nonDerivative · entry 2 Vittiglio Joseph · CIK 0001551776 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,380 F2 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 3,999 restricted stock units on March 2, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 18:07 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 986 | $14.76 | $14,553.36 |
DisclosureSEC source: 0000792977-19-000046 · wf-form4_155182724598001.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,526 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 3,001 restricted stock units on March 1, 2019. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 18:25 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $15.51 | Not disclosed |
DisclosureSEC source: 0000792977-19-000028 · wf-form4_155130991647075.xml · derivative · entry 3 Vittiglio Joseph · CIK 0001551776 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-02-25 F3 · price: Not applicable. F5 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 18:25 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 12,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000792977-19-000028 · wf-form4_155130991647075.xml · nonDerivative · entry 2 Vittiglio Joseph · CIK 0001551776 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,512 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F4 · shares: These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending February 25, 2022 subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award. F3 · price: Not applicable. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 18:25 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000792977-19-000028 · wf-form4_155130991647075.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,512 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F2 · shares: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Fourth Amended & Restated 2007 Equity Incentive Plan, as amended (the "Plan") that will vest in three equal annual installments with the first installment vesting on February 25, 2020. F3 · price: Not applicable. Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 17:44 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 869 | $15.51 | $13,478.19 |
DisclosureSEC source: 0000792977-19-000021 · wf-form4_155122105598895.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,512 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 2,500 restricted stock units on February 23, 2019. Read SEC document |
| August 24, 2018 Filed Aug 27, 2018 16:17 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 1,473 | $24.60 | $36,235.80 |
DisclosureSEC source: 0000792977-18-000057 · wf-form4_153540101316279.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,381 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 5,001 restricted stock units on August 24, 2018. Read SEC document |
| March 06, 2018 Filed Mar 6, 2018 19:25 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | SaleCommon Stock | 770 | $20.80 | $16,016.00 |
DisclosureSEC source: 0001179110-18-003697 · edgar.xml · nonDerivative · entry 5 Vittiglio Joseph · CIK 0001551776 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,854 F7 · kind: The reported transaction on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2017. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 19:25 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $21.00 | Not disclosed |
DisclosureSEC source: 0001179110-18-003697 · edgar.xml · derivative · entry 6 Vittiglio Joseph · CIK 0001551776 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-03-02 F4 · price: Not applicable. F8 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 19:25 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 1,011 | $21.00 | $21,231.00 |
DisclosureSEC source: 0001179110-18-003697 · edgar.xml · nonDerivative · entry 4 Vittiglio Joseph · CIK 0001551776 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,624 F6 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 3,000 RSUs on March 1, 2018. Due to the black-out policies implemented by the Issuer, the shares of the Issuer's Common Stock underlying such vested RSUs were not delivered to the reporting person until March 2, 2018, at which time an aggregate of 1,011 shares were withheld to satisfy the reporting person's applicable tax obligations. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 19:25 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-003697 · edgar.xml · nonDerivative · entry 3 Vittiglio Joseph · CIK 0001551776 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,635 F2 · shares: Each RSU represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F5 · shares: These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending March 1, 2021 subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered pursuant to the award ("Target Award"); however, the amount that vests could range from zero to 150% of the Target Award. F4 · price: Not applicable. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 19:25 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 12,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-003697 · edgar.xml · nonDerivative · entry 2 Vittiglio Joseph · CIK 0001551776 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,635 F2 · shares: Each RSU represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). F3 · shares: These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Fourth Amended and Restated 2007 Equity Incentive Plan (as amended the "Plan") and will vest in three equal annual installments with the first installment vesting on March 2, 2019. F4 · price: Not applicable. Read SEC document |
| February 23, 2018 Filed Mar 6, 2018 19:25 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 869 | $19.65 | $17,075.85 |
DisclosureSEC source: 0001179110-18-003697 · edgar.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,635 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 2,499 restricted stock units ("RSUs") on February 23, 2018. Read SEC document |
| August 29, 2017 Filed Aug 30, 2017 16:03 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | SaleCommon Stock | 1,250 | $16.75 | $20,937.50 |
DisclosureSEC source: 0001179110-17-011890 · edgar.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,504 F1 · shares: The reported transaction on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2017. Read SEC document |
| August 24, 2017 Filed Aug 28, 2017 16:27 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 1,633 | $17.50 | $28,577.50 |
DisclosureSEC source: 0001179110-17-011859 · edgar.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,754 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 5,000 restricted stock units on August 24, 2017. 1,633 shares were withheld to satisfy the reporting person's applicable tax obligations. Read SEC document |
| May 08, 2017 Filed May 10, 2017 16:45 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Tax withholdingCommon Stock | 980 | $18.55 | $18,179.00 |
DisclosureSEC source: 0001179110-17-006985 · edgar.xml · nonDerivative · entry 1 Vittiglio Joseph · CIK 0001551776 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,387 F1 · shares: Represents shares withheld to satisfy the reporting person's tax obligations in connection with the vesting of 2,999 restricted stock units ("RSUs") on March 1, 2017. Due to the black-out policies implemented by AMAG Pharmaceuticals, Inc. (the "Issuer"), the shares of the Issuer's Common Stock underlying such vested RSUs were not delivered to the reporting person until May 8, 2017, at which time 980 shares were withheld to satisfy the reporting person's applicable tax obligations. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 19:03 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $23.75 | Not disclosed |
DisclosureSEC source: 0001179110-17-003323 · edgar.xml · derivative · entry 3 Vittiglio Joseph · CIK 0001551776 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-02-23 F3 · price: Not applicable. F5 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.